title: [Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].
abstract: OBJECTIVE
  Vandetanib is a once-daily oral multi-target inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and rearranged during transfection (RET) tyrosine kinases. The current study aimed to evaluate the effect and safety of vandetanib administered in refractory advanced lung adenocarcinoma patients.
  
  
  METHODS
  Five patients who accepted chemotherapy and Tarceva therapy as first- and second-line treatments received vandetanib (300 mg, oral, once daily).
  
  
  RESULTS
  The effects are stable disease on two patients (40%) and progressive disease on three patients (60%). With a median follow-up of 36 months, one patient remained on follow-up. The median progression free survival (PFS) is 2 months, and the mean overall survival is 22.6 months. The adverse events include rash (n=2), skin change (n=2), paronychia (n=2), asymptomatic QTc prolongation (n=2), ST-T change (n=1), diarrhea (n=1), and increased transaminase (n=1).
  
  
  CONCLUSIONS
  There were lower incidences of severe side effects with vandetanib therapy in refractory advanced lung adenocarcinoma patients. The results of effect and safety of vandetanib are similar with the related reviewed articles.
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Guo
authors.forename: Junfang
authors.initials: J
authors.lastname: Tang
authors.forename: Qiyi
authors.initials: Q
authors.lastname: Meng
authors.forename: Yunzhong
authors.initials: Y
authors.lastname: Zhu
authors.forename: Liyan
authors.initials: L
authors.lastname: Xu
authors.forename: Heling
authors.initials: H
authors.lastname: Shi
authors.forename: Zhe
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000077192:Adenocarcinoma of Lung; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D010880:Piperidines; D011799:Quinazolines; C452423:vandetanib